Cellbricks Accelerates Organ Printing Vision with €10M Funding
March 27, 2026, 10:05 am
Cellbricks Therapeutics secured €10M. This capital propels their biofabricated human tissue implants. The Berlin-Boston biotech firm revolutionizes regenerative medicine. Their proprietary light-based bioprinting platform creates vascularized tissues. Initial targets: complex wound healing and breast reconstruction. The long-term vision: 3D-printed organs. Funding fuels preclinical validation. This moves towards human trials. Cellbricks addresses critical medical challenges. They aim to restore patient function.
Cellbricks Therapeutics, a leader in tissue engineering, recently secured €10 million in new funding. This significant investment fuels their ambitious goal. The company develops biofabricated human tissue implants. These are designed for regenerative medicine. The funding includes a €7 million Seed round. An additional €3 million in non-dilutive funds is under negotiation. Silicon Roundabout Ventures led the round. Germany’s Federal Agency for Breakthrough Innovation (SPRIND) participated. Existing investors ACT Venture Partners also contributed.
This capital empowers the next stage of translational development. Cellbricks is building a path to complex human tissue repair. Ultimately, they aim for 3D-printed organs. Their technology promises to transform patient care. It offers solutions for severe tissue damage. This includes complex wounds and soft tissue defects.
Cellbricks employs a unique biofabrication platform. It combines human cells with specialized biomaterials. The process is light-based. This method offers significant speed advantages. It operates 15 times faster than competing bioprinting approaches. The technology ensures large-volume tissue production. Critically, it maintains full vascularization. This provides essential nutrients and oxygen. Tissue constructs remain viable. They function within living systems. This ensures long-term health and integration.
The company initially focuses on adipose tissue implants. This addresses a critical unmet medical need. Patients with severe soft tissue loss suffer greatly. This includes full-thickness burns and blast injuries. Reconstructive defects also present challenges. Current medical solutions are often compromises. They involve invasive grafting or synthetic implants. These restore shape imperfectly. They rarely restore living function. Cellbricks offers true functional restoration. Their implants go beyond superficial covers. They aim for large, viable, and functional tissue.
Breast reconstruction is another key application. It utilizes similar materials. However, it demands much larger volumes. It also requires even greater vascularization. This builds on their core capabilities. Each step validates the platform’s potential. It demonstrates efficacy in complex scenarios. The focus on wound healing proves the system. It shows the ability to produce large, functional constructs. These work in large animal models. This paves the way for human clinical use.
The ultimate goal for Cellbricks is functional organ manufacturing. This includes liver tissue. Each step in their development strategy builds towards this. Tissue therapeutics serve as crucial validation milestones. They pave the way for complex organ function. The platform’s capabilities advance incrementally. Larger, highly vascularized constructs become possible. These are essential for organ-level repair and replacement. Breakthroughs in cell biology, specifically pluripotent stem cells, secure cell supply. This was once a major hurdle for organ-scale bioprinting.
Cellbricks boasts a truly integrated approach. All essential expertise resides in-house. This covers cells, biomaterials, bioprinters, software, and tissue maturation. Crucially, translational capabilities are also internal. This full spectrum of in-house expertise is unique. It enables rapid adaptation and innovation. Scientists can directly adjust materials or printing parameters. This ensures optimal tissue outcomes and accelerated development. The dedicated system produces human tissue efficiently and consistently. This gives Cellbricks a real competitive advantage.
The company pursues a strategic partnership model. They seek collaboration with large pharmaceutical companies. This accelerates clinical adoption. It generates early revenue through upfront payments. Milestone achievements trigger further payments. Royalties follow successful product launch. This business model is highly attractive for a small biotech firm. It avoids the need for massive, independent funding rounds. It provides a clear, accelerated path to market. It also supports future IPO potential. Cellbricks is already in discussions with major biopharma partners.
Cellbricks operates with offices in both Berlin and Boston. This dual presence offers strategic advantages. Berlin provides cost efficiency. Laboratory setup and staffing are more affordable. This helps manage operational expenses. Boston, conversely, offers unparalleled speed. Regulatory approvals move faster. Animal trials can take weeks instead of many months. This geographic strategy balances financial prudence with rapid innovation. It leverages the best of both biotech ecosystems. Most of the scientific and operational team resides in Berlin.
This significant funding allows for critical preclinical validation. It translates promise into concrete proof. Engineered human tissues will perform robustly in clinically relevant models. The lead adipose tissue implant program will advance swiftly. The company plans up to three preclinical animal studies. This generates essential data. It paves the direct path to human clinical trials. Cellbricks is driving medical science forward. They offer new hope for patients suffering from severe tissue damage. The future of regenerative medicine looks increasingly bright. The journey to functional, 3D-printed organs gains significant momentum.
Cellbricks Therapeutics, a leader in tissue engineering, recently secured €10 million in new funding. This significant investment fuels their ambitious goal. The company develops biofabricated human tissue implants. These are designed for regenerative medicine. The funding includes a €7 million Seed round. An additional €3 million in non-dilutive funds is under negotiation. Silicon Roundabout Ventures led the round. Germany’s Federal Agency for Breakthrough Innovation (SPRIND) participated. Existing investors ACT Venture Partners also contributed.
This capital empowers the next stage of translational development. Cellbricks is building a path to complex human tissue repair. Ultimately, they aim for 3D-printed organs. Their technology promises to transform patient care. It offers solutions for severe tissue damage. This includes complex wounds and soft tissue defects.
Cellbricks employs a unique biofabrication platform. It combines human cells with specialized biomaterials. The process is light-based. This method offers significant speed advantages. It operates 15 times faster than competing bioprinting approaches. The technology ensures large-volume tissue production. Critically, it maintains full vascularization. This provides essential nutrients and oxygen. Tissue constructs remain viable. They function within living systems. This ensures long-term health and integration.
The company initially focuses on adipose tissue implants. This addresses a critical unmet medical need. Patients with severe soft tissue loss suffer greatly. This includes full-thickness burns and blast injuries. Reconstructive defects also present challenges. Current medical solutions are often compromises. They involve invasive grafting or synthetic implants. These restore shape imperfectly. They rarely restore living function. Cellbricks offers true functional restoration. Their implants go beyond superficial covers. They aim for large, viable, and functional tissue.
Breast reconstruction is another key application. It utilizes similar materials. However, it demands much larger volumes. It also requires even greater vascularization. This builds on their core capabilities. Each step validates the platform’s potential. It demonstrates efficacy in complex scenarios. The focus on wound healing proves the system. It shows the ability to produce large, functional constructs. These work in large animal models. This paves the way for human clinical use.
The ultimate goal for Cellbricks is functional organ manufacturing. This includes liver tissue. Each step in their development strategy builds towards this. Tissue therapeutics serve as crucial validation milestones. They pave the way for complex organ function. The platform’s capabilities advance incrementally. Larger, highly vascularized constructs become possible. These are essential for organ-level repair and replacement. Breakthroughs in cell biology, specifically pluripotent stem cells, secure cell supply. This was once a major hurdle for organ-scale bioprinting.
Cellbricks boasts a truly integrated approach. All essential expertise resides in-house. This covers cells, biomaterials, bioprinters, software, and tissue maturation. Crucially, translational capabilities are also internal. This full spectrum of in-house expertise is unique. It enables rapid adaptation and innovation. Scientists can directly adjust materials or printing parameters. This ensures optimal tissue outcomes and accelerated development. The dedicated system produces human tissue efficiently and consistently. This gives Cellbricks a real competitive advantage.
The company pursues a strategic partnership model. They seek collaboration with large pharmaceutical companies. This accelerates clinical adoption. It generates early revenue through upfront payments. Milestone achievements trigger further payments. Royalties follow successful product launch. This business model is highly attractive for a small biotech firm. It avoids the need for massive, independent funding rounds. It provides a clear, accelerated path to market. It also supports future IPO potential. Cellbricks is already in discussions with major biopharma partners.
Cellbricks operates with offices in both Berlin and Boston. This dual presence offers strategic advantages. Berlin provides cost efficiency. Laboratory setup and staffing are more affordable. This helps manage operational expenses. Boston, conversely, offers unparalleled speed. Regulatory approvals move faster. Animal trials can take weeks instead of many months. This geographic strategy balances financial prudence with rapid innovation. It leverages the best of both biotech ecosystems. Most of the scientific and operational team resides in Berlin.
This significant funding allows for critical preclinical validation. It translates promise into concrete proof. Engineered human tissues will perform robustly in clinically relevant models. The lead adipose tissue implant program will advance swiftly. The company plans up to three preclinical animal studies. This generates essential data. It paves the direct path to human clinical trials. Cellbricks is driving medical science forward. They offer new hope for patients suffering from severe tissue damage. The future of regenerative medicine looks increasingly bright. The journey to functional, 3D-printed organs gains significant momentum.